| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Liver Cirrhosis | 7 | 2019 | 1810 | 1.47 | Why? |
| Acute-On-Chronic Liver Failure | 4 | 2019 | 237 | 0.99 | Why? |
| Sputum | 8 | 2020 | 1720 | 0.87 | Why? |
| Lipid Peroxidation | 1 | 2021 | 114 | 0.87 | Why? |
| Meningitis, Cryptococcal | 1 | 2021 | 79 | 0.83 | Why? |
| Hepatitis B, Chronic | 4 | 2019 | 616 | 0.76 | Why? |
| Ascites | 1 | 2017 | 65 | 0.70 | Why? |
| Hypertension, Portal | 1 | 2017 | 73 | 0.66 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2019 | 167 | 0.62 | Why? |
| Iron | 1 | 2021 | 619 | 0.58 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 533 | 0.53 | Why? |
| Virus Shedding | 5 | 2020 | 5834 | 0.51 | Why? |
| Cell- and Tissue-Based Therapy | 1 | 2018 | 422 | 0.51 | Why? |
| End Stage Liver Disease | 1 | 2018 | 418 | 0.50 | Why? |
| China | 37 | 2021 | 50654 | 0.46 | Why? |
| Cerebral Hemorrhage | 1 | 2019 | 820 | 0.44 | Why? |
| Renal Insufficiency | 1 | 2017 | 810 | 0.41 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.41 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2019 | 907 | 0.39 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.37 | Why? |
| Hepacivirus | 1 | 2018 | 1509 | 0.37 | Why? |
| Coronavirus Infections | 29 | 2020 | 253789 | 0.36 | Why? |
| Pneumonia, Viral | 28 | 2020 | 243684 | 0.36 | Why? |
| Lymphocytes | 2 | 2020 | 3056 | 0.36 | Why? |
| Bacterial Infections | 2 | 2018 | 2229 | 0.34 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.34 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.34 | Why? |
| Sustained Virologic Response | 2 | 2019 | 378 | 0.32 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.32 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.32 | Why? |
| B-Lymphocytes | 1 | 2020 | 4418 | 0.29 | Why? |
| Betacoronavirus | 26 | 2020 | 204454 | 0.29 | Why? |
| Liver Transplantation | 2 | 2018 | 2864 | 0.29 | Why? |
| Risk Factors | 21 | 2021 | 71621 | 0.28 | Why? |
| Tuberculosis | 1 | 2021 | 2895 | 0.28 | Why? |
| Vitamin D Deficiency | 1 | 2018 | 1782 | 0.28 | Why? |
| Indoles | 3 | 2020 | 1243 | 0.26 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.26 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.26 | Why? |
| Anti-Bacterial Agents | 4 | 2020 | 10083 | 0.24 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.23 | Why? |
| Middle Aged | 41 | 2021 | 270681 | 0.23 | Why? |
| Retrospective Studies | 27 | 2021 | 105322 | 0.23 | Why? |
| Male | 44 | 2021 | 367725 | 0.22 | Why? |
| Interferon-alpha | 2 | 2020 | 1442 | 0.22 | Why? |
| Female | 43 | 2021 | 380317 | 0.22 | Why? |
| gamma-Globulins | 1 | 2020 | 73 | 0.21 | Why? |
| Lymphocyte Count | 3 | 2020 | 4758 | 0.20 | Why? |
| Mycobacterium avium | 1 | 2019 | 10 | 0.20 | Why? |
| Cesarean Section | 2 | 2020 | 2089 | 0.20 | Why? |
| Mycobacterium kansasii | 1 | 2019 | 14 | 0.20 | Why? |
| Lipid Metabolism | 2 | 2021 | 572 | 0.19 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.19 | Why? |
| Adult | 35 | 2021 | 244371 | 0.19 | Why? |
| Hepatitis B e Antigens | 1 | 2019 | 99 | 0.19 | Why? |
| Glutathione | 1 | 2021 | 280 | 0.19 | Why? |
| Humans | 59 | 2021 | 930598 | 0.19 | Why? |
| Paracentesis | 1 | 2017 | 25 | 0.18 | Why? |
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2017 | 16 | 0.18 | Why? |
| Infusion Pumps, Implantable | 1 | 2017 | 31 | 0.18 | Why? |
| Nasal Sprays | 1 | 2020 | 234 | 0.18 | Why? |
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 98 | 0.18 | Why? |
| Antiviral Agents | 10 | 2020 | 41703 | 0.17 | Why? |
| Drug Therapy | 1 | 2020 | 280 | 0.17 | Why? |
| Hepatitis, Viral, Human | 1 | 2020 | 196 | 0.17 | Why? |
| Cross Infection | 2 | 2020 | 8675 | 0.17 | Why? |
| Hemoperfusion | 1 | 2020 | 260 | 0.16 | Why? |
| Disease Progression | 6 | 2021 | 13580 | 0.16 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Metabolome | 1 | 2021 | 624 | 0.16 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.16 | Why? |
| Ebola Vaccines | 1 | 2017 | 126 | 0.15 | Why? |
| Influenza A Virus, H7N9 Subtype | 1 | 2020 | 415 | 0.15 | Why? |
| RNA, Ribosomal, 16S | 1 | 2019 | 793 | 0.15 | Why? |
| Prognosis | 7 | 2021 | 32490 | 0.15 | Why? |
| Pandemics | 27 | 2020 | 389249 | 0.14 | Why? |
| Influenza in Birds | 1 | 2020 | 528 | 0.14 | Why? |
| Liver | 2 | 2020 | 4007 | 0.14 | Why? |
| Polyethylene Glycols | 1 | 2019 | 574 | 0.14 | Why? |
| Pregnancy Complications, Infectious | 1 | 2020 | 11559 | 0.13 | Why? |
| Aged | 20 | 2021 | 215776 | 0.13 | Why? |
| Goals | 1 | 2017 | 335 | 0.13 | Why? |
| Liver Failure, Acute | 1 | 2017 | 279 | 0.13 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2018 | 724 | 0.13 | Why? |
| Klebsiella Infections | 1 | 2019 | 466 | 0.13 | Why? |
| Plasma Exchange | 1 | 2020 | 763 | 0.13 | Why? |
| Liver Function Tests | 1 | 2020 | 1325 | 0.13 | Why? |
| Vasoconstrictor Agents | 1 | 2017 | 714 | 0.13 | Why? |
| Proportional Hazards Models | 3 | 2020 | 6543 | 0.13 | Why? |
| Furin | 1 | 2020 | 1054 | 0.13 | Why? |
| Microbial Sensitivity Tests | 2 | 2019 | 2886 | 0.12 | Why? |
| Klebsiella pneumoniae | 1 | 2019 | 658 | 0.12 | Why? |
| Invasive Pulmonary Aspergillosis | 1 | 2020 | 634 | 0.12 | Why? |
| Latent Tuberculosis | 1 | 2017 | 324 | 0.12 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2019 | 669 | 0.12 | Why? |
| beta-Lactamases | 1 | 2019 | 759 | 0.12 | Why? |
| Bipolar Disorder | 1 | 2020 | 744 | 0.11 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.11 | Why? |
| Gastrointestinal Tract | 1 | 2020 | 1113 | 0.11 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.11 | Why? |
| Leukocytes, Mononuclear | 1 | 2021 | 2115 | 0.11 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.11 | Why? |
| Cytokines | 4 | 2020 | 15010 | 0.11 | Why? |
| Polymorphism, Genetic | 1 | 2018 | 1074 | 0.11 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.11 | Why? |
| RNA, Viral | 5 | 2020 | 32276 | 0.11 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.10 | Why? |
| Ebolavirus | 1 | 2017 | 834 | 0.10 | Why? |
| Leukocytes | 1 | 2017 | 1046 | 0.10 | Why? |
| Glucocorticoids | 3 | 2020 | 4431 | 0.10 | Why? |
| Phenotype | 2 | 2018 | 4037 | 0.10 | Why? |
| Critical Illness | 4 | 2020 | 17281 | 0.10 | Why? |
| Mycobacterium tuberculosis | 1 | 2019 | 1164 | 0.10 | Why? |
| Case-Control Studies | 4 | 2020 | 17671 | 0.09 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.09 | Why? |
| Microbiota | 1 | 2019 | 1240 | 0.09 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.09 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.09 | Why? |
| Predictive Value of Tests | 3 | 2019 | 9537 | 0.09 | Why? |
| Pregnancy | 2 | 2020 | 23879 | 0.09 | Why? |
| Gastrointestinal Microbiome | 1 | 2021 | 1961 | 0.09 | Why? |
| Darunavir | 2 | 2020 | 477 | 0.08 | Why? |
| Pregnancy Outcome | 1 | 2020 | 3803 | 0.08 | Why? |
| Time Factors | 5 | 2020 | 31397 | 0.08 | Why? |
| Feces | 4 | 2021 | 4235 | 0.08 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.08 | Why? |
| Radiography, Thoracic | 2 | 2020 | 5486 | 0.08 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.08 | Why? |
| Monocytes | 1 | 2018 | 2978 | 0.08 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2017 | 1475 | 0.08 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.08 | Why? |
| Nutritional Support | 2 | 2020 | 447 | 0.07 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.07 | Why? |
| Aged, 80 and over | 6 | 2020 | 88759 | 0.07 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.07 | Why? |
| Viral Load | 3 | 2020 | 15850 | 0.07 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.07 | Why? |
| Protease Inhibitors | 1 | 2020 | 3630 | 0.07 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.07 | Why? |
| T-Lymphocytes | 2 | 2018 | 6670 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| World Health Organization | 1 | 2017 | 4213 | 0.07 | Why? |
| Signal Transduction | 1 | 2021 | 7207 | 0.07 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.07 | Why? |
| Young Adult | 9 | 2020 | 93724 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.06 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.06 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2020 | 5164 | 0.06 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.06 | Why? |
| Interleukin-10 | 2 | 2020 | 1409 | 0.06 | Why? |
| Vitamin D | 1 | 2018 | 2904 | 0.06 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.06 | Why? |
| Fever | 4 | 2020 | 7795 | 0.06 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.06 | Why? |
| Adolescent | 7 | 2021 | 86841 | 0.06 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Immunogenicity, Vaccine | 1 | 2017 | 4624 | 0.06 | Why? |
| Tomography, X-Ray Computed | 4 | 2021 | 25144 | 0.06 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.06 | Why? |
| Toll-Like Receptor 6 | 1 | 2021 | 44 | 0.06 | Why? |
| Lung | 2 | 2020 | 31049 | 0.06 | Why? |
| Fructose | 1 | 2021 | 52 | 0.05 | Why? |
| Early Diagnosis | 2 | 2020 | 2443 | 0.05 | Why? |
| Follow-Up Studies | 4 | 2021 | 17020 | 0.05 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.05 | Why? |
| Hydroxybutyrates | 1 | 2021 | 162 | 0.05 | Why? |
| Gas Chromatography-Mass Spectrometry | 1 | 2021 | 187 | 0.05 | Why? |
| Biomarkers | 3 | 2019 | 23361 | 0.05 | Why? |
| Adverse Outcome Pathways | 1 | 2020 | 63 | 0.05 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2021 | 6166 | 0.05 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2021 | 211 | 0.05 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.05 | Why? |
| Codon | 1 | 2020 | 287 | 0.05 | Why? |
| Water-Electrolyte Balance | 1 | 2020 | 136 | 0.05 | Why? |
| Lymphotoxin-alpha | 1 | 2018 | 15 | 0.05 | Why? |
| Cobicistat | 1 | 2020 | 172 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Influenza, Human | 2 | 2021 | 10779 | 0.05 | Why? |
| Gene Expression Regulation, Bacterial | 1 | 2019 | 143 | 0.05 | Why? |
| Sodium | 1 | 2020 | 309 | 0.04 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.04 | Why? |
| Albumins | 1 | 2020 | 324 | 0.04 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.04 | Why? |
| Lactic Acid | 1 | 2021 | 393 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2019 | 22971 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2019 | 305 | 0.04 | Why? |
| Interleukin-4 | 1 | 2018 | 367 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Cloud Computing | 1 | 2019 | 214 | 0.04 | Why? |
| Amino Acids | 1 | 2021 | 552 | 0.04 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 6653 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2020 | 399 | 0.04 | Why? |
| Interleukin-2 | 1 | 2018 | 443 | 0.04 | Why? |
| Inflammation Mediators | 2 | 2019 | 2654 | 0.04 | Why? |
| Cholesterol | 1 | 2021 | 660 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Pharyngitis | 1 | 2020 | 687 | 0.04 | Why? |
| Cough | 2 | 2020 | 4891 | 0.04 | Why? |
| Chest Pain | 1 | 2020 | 578 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Antigens, CD | 1 | 2021 | 984 | 0.04 | Why? |
| Markov Chains | 1 | 2017 | 502 | 0.04 | Why? |
| DNA, Bacterial | 1 | 2019 | 835 | 0.04 | Why? |
| Injections, Intramuscular | 1 | 2017 | 800 | 0.03 | Why? |
| Iatrogenic Disease | 1 | 2017 | 304 | 0.03 | Why? |
| Fomites | 1 | 2020 | 709 | 0.03 | Why? |
| Hospital Mortality | 1 | 2017 | 22087 | 0.03 | Why? |
| Aspartate Aminotransferases | 1 | 2020 | 1394 | 0.03 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.03 | Why? |
| Probiotics | 1 | 2020 | 694 | 0.03 | Why? |
| Shock | 1 | 2020 | 1868 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Prevalence | 3 | 2019 | 25773 | 0.03 | Why? |
| L-Lactate Dehydrogenase | 1 | 2020 | 1995 | 0.03 | Why? |
| Animals | 2 | 2020 | 78931 | 0.03 | Why? |
| Propensity Score | 1 | 2020 | 2690 | 0.03 | Why? |
| Phylogeny | 2 | 2020 | 13341 | 0.03 | Why? |
| Antipsychotic Agents | 1 | 2020 | 887 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Sequence Analysis, RNA | 1 | 2020 | 2290 | 0.03 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Community Health Services | 1 | 2019 | 1000 | 0.03 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.03 | Why? |
| Mutation | 2 | 2020 | 12376 | 0.03 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2021 | 3788 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2019 | 1414 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2019 | 3786 | 0.02 | Why? |
| Interferon-gamma | 1 | 2018 | 2711 | 0.02 | Why? |
| Antibodies, Viral | 2 | 2020 | 51949 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.02 | Why? |
| Africa | 1 | 2017 | 2986 | 0.02 | Why? |
| Membrane Glycoproteins | 1 | 2017 | 2273 | 0.02 | Why? |
| Diabetes Complications | 1 | 2020 | 2358 | 0.02 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.02 | Why? |
| Body Mass Index | 1 | 2021 | 4306 | 0.02 | Why? |
| Interferon Type I | 1 | 2021 | 2789 | 0.02 | Why? |
| Medicine, Chinese Traditional | 1 | 2020 | 2255 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2020 | 3691 | 0.02 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.02 | Why? |
| Child | 3 | 2020 | 70012 | 0.02 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 2984 | 0.02 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Liver Diseases | 1 | 2020 | 2698 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.02 | Why? |
| Transcriptome | 1 | 2017 | 3466 | 0.02 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Magnetic Resonance Imaging | 1 | 2020 | 6551 | 0.02 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.02 | Why? |
| Brain | 1 | 2020 | 5133 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2017 | 4849 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.01 | Why? |
| Interleukin-6 | 1 | 2018 | 7522 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.01 | Why? |
| Health Policy | 1 | 2019 | 6242 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Stress, Psychological | 1 | 2020 | 10231 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2017 | 25288 | 0.01 | Why? |